Oncotelic issues $0.5M convertible note to Golden Mountain Partners as part of $1.5M funding

Oncotelic Therapeutics, Inc.

Issued $0.5M unsecured convertible note to Golden Mountain Partners, part of up to $1.5M total in three monthly installments.
Note carries 2% annual interest, matures one year from date, convertible into common stock at closing bid price.
Proceeds to support payroll and clinical development of OT-101.
Note contains standard events of default; prepayment allowed with accrued interest.
Conversion shares unregistered, issued under Rule 506.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.